

## A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153

**Status:** Recruiting

### Eligibility Criteria

**Age:** 18 years and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

#### Inclusion Criteria:

- at least 18 years old - diagnosis of non-small cell lung cancer (NSCLC) - tumor size between 1 and 4 cm in size - had a complete surgical resection of stage I NSCLC between 4-12 weeks ago - able to walk and carry out basic activities of living - women are willing to use highly effective birth control for 120 days after last dose of study drug - certain laboratory values are required (study staff will review)

#### Exclusion Criteria:

- chemotherapy, radiation therapy, or immunotherapy for the treatment of this lung cancer - active additional cancer that is progressing or has required treatment within the past 3 years - diagnosis of immunodeficiency or receiving chronic steroid therapy - women who are pregnant or breast feeding - other active diseases (study staff will review)

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Clinics and Surgery Center (CSC)

### More Information

**Description:** The primary objective is to evaluate whether the addition of adjuvant Pembrolizumab following surgical resection improves disease free survival compared with observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm in size, regardless of PD-L1 TPS score.

**Contact(s):** Amit Kulkarni - kulkarni@umn.edu

**Principal Investigator:** Amit Kulkarni

**IRB**

**Number:** STUDY00010745

**System ID:** 29878

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.